Clinical Trial Search

Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day

Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…

Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…

Primary: Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item. — 13 Participants

Primary: IBS (Irritable Bowel Syndrome) Symptom Severity Score (Total Score) — 256.9; 84.4 units on a scale

Primary: Effectiveness of Group Hypnotherapy in Irritable Bowel Syndrome

Primary: Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2) — 17.57; 16.2; 18.76 mL/mm Hg

Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants

Primary: Colonic Transit Geometric Center at 24 Hours — 3.12; 3.05; 2.77 units on a scale

Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78

Primary: Clinical Global Impressions - Improvement Scale (CGI-I; Patient Version) — 68.1; 64.6; 46.7; 64.0 percentage of treatment responders

Primary: Response of Overall IBS Symptom Relief - 50% Rule — 79; 61; 61; 78 Participants

Primary: Abdominal Pain Intensity Responder — 55; 49 Participants — p=0.5352

Primary: Mean Pain Bowel Symptom Scale (BSS) Score Over Last 4 Weeks of Study (Weeks 9-12) — 25.3; 42.0 units on a scale — p=0.008

Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours

Primary: Lactulose Mannitol Excretion — 512.5; 394.5; 456.8; 411 micrograms per ml

Primary: Overall Bowel Symptom Scores (BSS) — 76; 44 Scores on a scale

Primary: A Change in Length of Spread of Antegrade Contractions After Placebo.

Primary: Comparison of the Phase Angle Between IBS Patients and Healthy Individuals — 5.78; 6.35 degrees

Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants

Primary: Retention Rate — 23; 25; 19; 22 Participants

Primary: Number of Participants With Worsening Irritable Bowel Syndrome (IBS) Symptoms Based on IBS-SSS — 8; 10; 11 Participants

Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001

Primary: Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). — 31.2…

Primary: Change in the Irritable Bowel Symptom Severity Scale — 181; 301 units on a scale

Primary: Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). — 32.2…

Primary: Percentage of Participants With Overall Response — 25.0; 17.1; 23.4; 17.8 Percentage of Participants — p=0.152

Primary: IBS Symptom Severity Score at 12 Weeks — 184.7 score on a scale

Primary: Repeat Treatment Responders — 32.6; 25.0 percentage of patients — p=0.0232

Primary: Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994). — -1.5 Units on a scale — p=<0.001